Cellular Biomedicine Group Enters Into Definitive Agreement to Acquire CD40LGVAX Vaccine and Related Technologies and Know-How Which Will be Used in a Pending PD-1 Combination Clinical Trial in the U.S. for Non-Small Cell Lu